Biotech companies operate clinical programs where one program is the company. Every operational shortcut is a strategic risk. Every operational over-build is a runway problem. PrismCDM is the regulated operating substrate built for that stage: the same architecture the largest sponsors use, scoped to your program.
One program is the company. Every operational shortcut is a strategic risk. Every operational over-build is a runway problem.
PrismCDM is the same regulated operating system whether the company runs one program or a hundred. Biotech companies get the same architecture, scoped to the program, without the operational over-build.
PrismCDM allows a small clinical organization to operate with the discipline of a much larger sponsor. The platform standardizes Trial Intelligence, execution, evidence, and submission without requiring a large internal operations organization.
PTII™ composite and sub-indices on every version of the protocol. Amendment risk, eligibility strictness, and enrollment velocity surface before they become operational issues.
Continuous evidence accumulation across the program. When the investor, the acquirer, or the regulator asks, the Inspection Evidence Package is one click away.
Every value carries an evidence classification, every artifact carries integrity anchors. Your team can use AI on the program without inheriting the inspection risk of an AI assistant.
Operate the substrate yourself, give the CRO scoped access, or let the CRO operate on your behalf. The substrate is the same in any configuration. Many vendors try to replace CROs; PrismCDM lets you run both on the same substrate.
PrismCDM grows with the program from IND through submission without requiring a platform replacement as the company scales. The substrate is the same in Phase 1 as in Phase 3 as in commercialization.
Four-anchor integrity chain on every artifact. Acquirers, partners, regulators, and investors can independently validate your operational history. Nothing is reconstructed during diligence.
PrismCDM is the substrate underneath the program from the earliest research through commercialization. Same architecture in Phase 1 as in submission as in due diligence.
Three reasons biotech leadership adopt PrismCDM. The reasons their leadership teams remember after the room clears.
The same regulated operating substrate the largest sponsors use, scoped to your program. Built once, used for the life of the company.
You are buying enterprise architecture, not enterprise overhead. The platform standardizes operations without requiring a large internal team.
Operational maturity is now part of fundraising, partnering, and acquisition diligence. PrismCDM helps demonstrate that maturity from the beginning of the program instead of reconstructing it later.
